Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336730 | 1.00 | EPHX2 (0.47) | EPHX2TPSAB1TPSD1TPSG1GPR139 | |
| SCHEMBL3336687 | 0.87 | TPSAB1 (0.48) | EPHX2TPSAB1TPSD1TPSG1 | |
| SCHEMBL3333854 | 0.87 | TPSAB1 (0.48) | EPHX2TPSAB1TPSD1TPSG1 | |
| SCHEMBL4697644 | 0.81 | TPSAB1 (0.50) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3335469 | 0.78 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3332397 | 0.78 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL4697341 | 0.76 | TPSAB1 (0.58) | EPHX2TPSAB1TPSD1TPSG1 | |
| SCHEMBL4697345 | 0.76 | TPSAB1 (0.58) | EPHX2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7443391 | 0.74 | ELANE (0.49) | TPSAB1TPSD1TPSG1 | |
| Hydrochloric Acid SCHEMBL7320686 | 0.73 | ELANE (0.48) | TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | EPHX2 853/4885TPSAB1 14/4885TPSD1 24/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | EPHX2 853/4885TPSAB1 14/4885TPSD1 24/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | EPHX2 853/4885TPSAB1 14/4885TPSD1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.